No deviation in use of preferential issue proceeds for Q1 FY27
BETA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Beta Drugs confirmed no deviation in use of Rs 117.01 crore raised via preferential issue on November 25, 2024, for the quarter ended June 30, 2026. Of Rs 117 crore allocated across seven objects, Rs 47.87 crore has been utilised so far. Major usage: Rs 19.95 crore for capital investments, Rs 13.85 crore for general corporate, Rs 9.52 crore for new manufacturing setup. Geographical expansion saw zero spending, while R&D facility used only Rs 0.95 crore of the Rs 15 crore allocated. Brickwork Ratings is the monitoring agency.
Funds used as promised. Slow utilisation in R&D and geographical expansion (zero spend) may concern investors expecting faster deployment.